{"pmid":32503853,"title":"COVID-19 infection in a patient with FMF: does colchicine have a protective effect?","text":["COVID-19 infection in a patient with FMF: does colchicine have a protective effect?","Ann Rheum Dis","Kobak, Senol","32503853"],"journal":"Ann Rheum Dis","authors":["Kobak, Senol"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503853","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/annrheumdis-2020-217882","keywords":["antirheumatic agents","familial mediterranean fever","patient care team"],"e_drugs":["Colchicine"],"topics":["Case Report"],"weight":1,"_version_":1668892488224473090,"score":9.490897,"similar":[{"pmid":32503855,"title":"Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.","text":["Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.","Ann Rheum Dis","Monti, Sara","Montecucco, Carlomaurizio","32503855"],"journal":"Ann Rheum Dis","authors":["Monti, Sara","Montecucco, Carlomaurizio"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503855","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/annrheumdis-2020-217957","keywords":["antirheumatic agents","cytokines","familial mediterranean fever"],"locations":["Kobak"],"e_drugs":["Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1668892488174141440,"score":121.3703},{"pmid":32299796,"title":"Antirheumatic agents in covid-19: is IL-6 the right target?","text":["Antirheumatic agents in covid-19: is IL-6 the right target?","Ann Rheum Dis","Capecchi, Pier Leopoldo","Lazzerini, Pietro Enea","Volterrani, Luca","Mazzei, Maria Antonietta","Rossetti, Barbara","Zanelli, Giacomo","Bennett, David","Bargagli, Elena","Franchi, Federico","Cameli, Matteo","Valente, Serafina","Cantarini, Luca","Frediani, Bruno","32299796"],"journal":"Ann Rheum Dis","authors":["Capecchi, Pier Leopoldo","Lazzerini, Pietro Enea","Volterrani, Luca","Mazzei, Maria Antonietta","Rossetti, Barbara","Zanelli, Giacomo","Bennett, David","Bargagli, Elena","Franchi, Federico","Cameli, Matteo","Valente, Serafina","Cantarini, Luca","Frediani, Bruno"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299796","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1136/annrheumdis-2020-217523","keywords":["antirheumatic agents","cardiovascular diseases","inflammation","patient care team"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494831951873,"score":63.779697},{"pmid":32503854,"title":"EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.","text":["EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.","The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a 'living document' and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available.","Ann Rheum Dis","Landewe, Robert Bm","Machado, Pedro M","Kroon, Feline","Bijlsma, Hans Wj","Burmester, Gerd R","Carmona, Loreto","Combe, Bernard","Galli, Massimo","Gossec, Laure","Iagnocco, Annamaria","Isaacs, John D","Mariette, Xavier","McInnes, Iain","Mueller-Ladner, Ulf","Openshaw, Peter","Smolen, Josef S","Stamm, Tanja A","Wiek, Dieter","Schulze-Koops, Hendrik","32503854"],"abstract":["The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a 'living document' and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available."],"journal":"Ann Rheum Dis","authors":["Landewe, Robert Bm","Machado, Pedro M","Kroon, Feline","Bijlsma, Hans Wj","Burmester, Gerd R","Carmona, Loreto","Combe, Bernard","Galli, Massimo","Gossec, Laure","Iagnocco, Annamaria","Isaacs, John D","Mariette, Xavier","McInnes, Iain","Mueller-Ladner, Ulf","Openshaw, Peter","Smolen, Josef S","Stamm, Tanja A","Wiek, Dieter","Schulze-Koops, Hendrik"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503854","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/annrheumdis-2020-217877","keywords":["antirheumatic agents","epidemiology","health services research","patient care team","quality indicators, health care"],"topics":["Prevention"],"weight":1,"_version_":1668892488203501568,"score":63.779697}]}